Beta Bionics, Inc. Common Stock (BBNX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Beta Bionics, Inc. Common Stock (BBNX) has a cash flow conversion efficiency ratio of -0.057x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.62 Million) by net assets ($256.37 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Beta Bionics, Inc. Common Stock worth for the company's overall valuation and market capitalisation.
Beta Bionics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Beta Bionics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Beta Bionics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Beta Bionics, Inc. Common Stock ranked by their cash flow conversion efficiency. See BBNX operating cash to total liabilities to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hefei Fengle Seed Co Ltd
SHE:000713
|
0.076x |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
0.051x |
|
Hunan Jingfeng Pharmaceutical
SHE:000908
|
-3.332x |
|
Zhejiang Changhua Auto Parts Co Ltd
SHG:605018
|
0.048x |
|
LIGHTHOUSE PROPERTIES
F:87O
|
N/A |
|
Cryoport Inc
NASDAQ:CYRX
|
0.002x |
|
Renta 4 Banco S.A
MC:R4
|
0.028x |
|
Metro Healthcare Indonesia
JK:CARE
|
0.005x |
Annual Cash Flow Conversion Efficiency for Beta Bionics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Beta Bionics, Inc. Common Stock from 2022 to 2025. View BBNX live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $287.61 Million | $-50.92 Million | -0.177x | +72.12% |
| 2024-12-31 | $76.01 Million | $-48.27 Million | -0.635x | -14.72% |
| 2023-12-31 | $58.61 Million | $-32.45 Million | -0.554x | -256.34% |
| 2022-12-31 | $-170.03 Million | $-60.21 Million | 0.354x | -- |
About Beta Bionics, Inc. Common Stock
Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Pa… Read more